NCT01623323 - Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps | Biotech Hunter

Enrollment

705

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Chronic Sinusitis With or Without Nasal Polyps

Interventions

DRUG

Fluticasone Propionate

Fluticasone Propionate 400 μg

Trial Locations (18)

10994

ENT and Allergy Associates, West Nyack

12553

ENT and Allergy Associates, New Windsor

20902

Institute for Asthma and Allergy, Wheaton

30030

ENT of Georgia, Decatur

33778

Sher Allergy, Largo

59718

Clinical Research Group of Montana, Bozeman

70115

Best Clinical Trials, New Orleans

74136

Vital Prospects Clinical Research Institute, Tulsa

78233

Live Oak Allergy and Asthma Clinic, Live Oak

78256

Texas Quest Medical Research, San Antonio

80909

Colorado ENT and Allergy, Colorado Springs

84020

Focus Clinical Research, Draper

84088

Advanced Clinical Research, West Jordan

84102

InterMountain Ear Nose and Throat, Salt Lake City

84790

Chrysalis Clinical Research, St. George

85032

Precision Trials, Phoenix

97202

Allergy Associates Research Center, Portland

99204

Premier Clinical Research, Spokane

All Listed Sponsors

lead

Optinose US Inc.

INDUSTRY